ES2684349T3 - Péptidos y composiciones para el tratamiento de daños de las articulaciones. - Google Patents

Péptidos y composiciones para el tratamiento de daños de las articulaciones. Download PDF

Info

Publication number
ES2684349T3
ES2684349T3 ES14713728.5T ES14713728T ES2684349T3 ES 2684349 T3 ES2684349 T3 ES 2684349T3 ES 14713728 T ES14713728 T ES 14713728T ES 2684349 T3 ES2684349 T3 ES 2684349T3
Authority
ES
Spain
Prior art keywords
seq
polypeptide
amino acid
angptl3
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14713728.5T
Other languages
English (en)
Spanish (es)
Inventor
Kristen Johnson
Jian Shi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2684349T3 publication Critical patent/ES2684349T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1891Angiogenesic factors; Angiogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof
    • A61K38/012Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1875Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/225Calcitonin gene related peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/515Angiogenesic factors; Angiogenin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655Chondrocytes; Cartilage
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/17Angiopoietin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
ES14713728.5T 2013-03-08 2014-03-07 Péptidos y composiciones para el tratamiento de daños de las articulaciones. Active ES2684349T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361775400P 2013-03-08 2013-03-08
US201361775400P 2013-03-08
US201461938123P 2014-02-10 2014-02-10
US201461938123P 2014-02-10
PCT/US2014/022102 WO2014138687A1 (en) 2013-03-08 2014-03-07 Peptides and compositions for treatment of joint damage

Publications (1)

Publication Number Publication Date
ES2684349T3 true ES2684349T3 (es) 2018-10-02

Family

ID=50390286

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14713728.5T Active ES2684349T3 (es) 2013-03-08 2014-03-07 Péptidos y composiciones para el tratamiento de daños de las articulaciones.

Country Status (38)

Country Link
US (4) US9649359B2 (https=)
EP (2) EP2964250B1 (https=)
JP (3) JP6567429B2 (https=)
KR (1) KR102267341B1 (https=)
CN (2) CN105025917B (https=)
AP (1) AP2015008675A0 (https=)
AU (3) AU2014225348B2 (https=)
BR (2) BR122016021558B1 (https=)
CA (1) CA2903448C (https=)
CL (1) CL2015002443A1 (https=)
CO (1) CO7461145A2 (https=)
CR (2) CR20200290A (https=)
CU (1) CU24301B1 (https=)
CY (1) CY1120729T1 (https=)
DK (1) DK2964250T3 (https=)
EA (1) EA035158B1 (https=)
EC (1) ECSP15042898A (https=)
ES (1) ES2684349T3 (https=)
HR (1) HRP20181269T1 (https=)
HU (1) HUE038499T2 (https=)
IL (1) IL240727B (https=)
JO (1) JO3564B1 (https=)
LT (1) LT2964250T (https=)
MX (1) MX365157B (https=)
MY (1) MY173172A (https=)
NZ (1) NZ711037A (https=)
PE (1) PE20151528A1 (https=)
PH (1) PH12015501983B1 (https=)
PL (1) PL2964250T3 (https=)
PT (1) PT2964250T (https=)
RS (1) RS57446B1 (https=)
SG (1) SG11201506490TA (https=)
SI (1) SI2964250T1 (https=)
TN (1) TN2015000385A1 (https=)
TW (1) TWI634124B (https=)
UY (1) UY35368A (https=)
WO (1) WO2014138687A1 (https=)
ZA (1) ZA201505966B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010273570B2 (en) 2009-07-14 2014-07-03 Novartis Ag Mesenchymal stem cell differentiation
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
US20190245180A1 (en) 2016-10-24 2019-08-08 Sumitomo Chemical Company, Limited Separator and secondary battery including the separator
WO2018088813A2 (ko) * 2016-11-09 2018-05-17 아이씨엠 주식회사 Nkx3.2 단편 및 이를 유효성분으로 포함하는 약학 조성물
CN109963579A (zh) * 2016-11-14 2019-07-02 诺华股份有限公司 用于治疗软骨损伤和关节炎的方法和组合物
CN108530619B (zh) * 2017-03-01 2020-12-08 北京大学第三医院 功能化氨基酸、制备方法及由其制得的功能化氨基酸水凝胶
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
MA53388A (fr) 2018-07-25 2021-06-02 Novartis Ag Inhibiteurs d'inflammasome nlrp3
AR116566A1 (es) * 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
EP3993820A4 (en) * 2019-07-04 2023-08-16 Cadila Healthcare Limited VACCINE BASED ON ANGPTL3 FOR THE TREATMENT OF LIVER DISEASES
KR102577697B1 (ko) 2019-11-13 2023-09-14 주식회사 나이벡 염증 및 상처 치료용 펩타이드
JP7298496B2 (ja) 2020-01-31 2023-06-27 トヨタ自動車株式会社 車両
JP2024519893A (ja) 2021-05-24 2024-05-21 ノバルティス アーゲー 変形性関節症の治療方法
TW202306970A (zh) 2021-05-24 2023-02-16 瑞士商諾華公司 用於治療骨關節炎之方法
CN113683681B (zh) * 2021-09-15 2023-10-03 山西锦波生物医药股份有限公司 一种重组i型人源化胶原蛋白c1l3t及其制备方法和用途
CN113683678B (zh) * 2021-09-15 2023-11-24 山西锦波生物医药股份有限公司 一种重组i型人源化胶原蛋白c1l2t及其制备方法和用途
CN118251594A (zh) 2021-11-10 2024-06-25 诺华股份有限公司 用于确定angptl多肽的生物活性的方法
CN114377202B (zh) * 2021-12-16 2023-01-24 方向前 适用于软骨再生的功能化自组装miRNA/多肽复合水凝胶及其制备方法
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
KR20240087877A (ko) * 2022-12-09 2024-06-20 (주)케어젠 연골 재생용 펩타이드 및 이의 용도
WO2025169047A1 (en) 2024-02-05 2025-08-14 Novartis Ag Improved production of angptl3 mimetics

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5288931A (en) 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
WO1999055869A1 (en) 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
EP1078046A4 (en) 1998-05-12 2005-05-11 Human Genome Sciences Inc 97 HUMAN SECRETED PROTEINS
AU4643699A (en) 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
EP1159419A1 (en) 1999-03-08 2001-12-05 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
GB9912350D0 (en) 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
AU4011300A (en) 1999-07-20 2001-02-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
JP4202128B2 (ja) 2000-10-16 2008-12-24 ジェネンテック・インコーポレーテッド Wispポリペプチドを用いる治療方法
US20040249141A1 (en) 2000-10-16 2004-12-09 Audrey Goddard Tie ligand homologues
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
US20030027751A1 (en) 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US7083970B2 (en) 2001-04-19 2006-08-01 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
FI117667B (fi) 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
JP5105696B2 (ja) 2001-11-16 2012-12-26 ジェネンテック, インコーポレイテッド アンジオポエチン様タンパク質3Angptl3含有組成物とその使用方法
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
NZ540490A (en) 2002-09-09 2007-10-26 Nektar Therapeutics Al Corp Water-soluble polymer alkanal conjugates with human growth hormone
ES2324608T3 (es) 2002-10-16 2009-08-11 The Scripps Research Institute Incorporacion especifica de sitio de cetoaminoacidos en proteinas.
MXPA05003978A (es) 2002-10-16 2005-06-22 Scripps Research Inst Sintesis de glicoproteinas.
WO2004094593A2 (en) 2003-04-17 2004-11-04 The Scripps Research Institute Expanding the eukaryotic genetic code
US20060160175A1 (en) 2003-07-07 2006-07-20 The Scripps Research Institute Compositions of orthogonal leucyl-trna and aminoacyl-trna synthetase pairs and uses thereof
WO2005019415A2 (en) 2003-07-07 2005-03-03 The Scripps Research Institute Compositions of orthogonal lysyl-trna and aminoacyl-trna synthetase pairs and uses thereof
WO2005007624A2 (en) 2003-07-07 2005-01-27 The Scripps Research Institute Compositions of orthogonal glutamyl-trna and aminoacyl trna synthetase pairs and uses thereof
CA2580840A1 (en) 2004-09-21 2006-03-30 The Scripps Research Institute In vivo incorporation of alkynyl amino acids into proteins in eubacteria
EP1807515A4 (en) 2004-10-27 2008-06-18 Scripps Research Inst Orthogonal translation components for the in vivo incorporation of unnatural amino acids
AU2006223579A1 (en) 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP5139271B2 (ja) 2005-05-24 2013-02-06 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 培養した造血幹細胞を拡大しかつ分析する方法
US7960141B2 (en) 2006-03-09 2011-06-14 The Scripps Research Institute Systems for the expression of orthogonal translation components in eubacterial host cells
AU2007328871B2 (en) 2006-12-06 2013-11-21 Seikagaku Corporation Pharmaceutical agent having long-lasting effect of treating arthritic disorders
PL2121751T3 (pl) 2006-12-08 2017-07-31 Lexicon Pharmaceuticals, Inc. Przeciwciała monoklonalne przeciwko ANGPTL3
EP2118150B1 (en) 2007-02-14 2015-09-23 Biocompatibles UK Limited Derivatisation of biological molecules
JP2010525836A (ja) 2007-05-04 2010-07-29 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ヒト造血幹細胞のexvivo増殖
AU2010273570B2 (en) * 2009-07-14 2014-07-03 Novartis Ag Mesenchymal stem cell differentiation
EP2670847B1 (en) 2011-02-03 2016-10-05 XOMA Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
EP2864360B1 (en) 2012-06-25 2017-09-06 The Brigham and Women's Hospital, Inc. Targeted therapeutics
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل

Also Published As

Publication number Publication date
UY35368A (es) 2014-10-31
EP3391900A1 (en) 2018-10-24
CA2903448A1 (en) 2014-09-12
JP6567429B2 (ja) 2019-08-28
CN105025917A (zh) 2015-11-04
EA201591661A1 (ru) 2015-12-30
IL240727B (en) 2019-12-31
LT2964250T (lt) 2018-07-25
NZ711037A (en) 2018-07-27
PL2964250T3 (pl) 2018-10-31
US10328126B2 (en) 2019-06-25
JP2020015725A (ja) 2020-01-30
CA2903448C (en) 2021-03-23
BR112015021269A2 (pt) 2017-10-10
ECSP15042898A (es) 2019-03-29
CR20150466A (es) 2015-10-27
HUE038499T2 (hu) 2018-10-29
JO3564B1 (ar) 2020-07-05
PH12015501983B1 (en) 2020-09-25
HK1214754A1 (en) 2016-08-05
KR20150125712A (ko) 2015-11-09
MY173172A (en) 2020-01-02
TWI634124B (zh) 2018-09-01
WO2014138687A1 (en) 2014-09-12
PT2964250T (pt) 2018-10-19
BR112015021269B1 (pt) 2023-04-11
EA035158B1 (ru) 2020-05-06
IL240727A0 (en) 2015-10-29
US20220184182A1 (en) 2022-06-16
CR20200290A (es) 2020-08-27
CU24301B1 (es) 2017-12-08
CU20150097A7 (es) 2016-05-30
US11179442B2 (en) 2021-11-23
JP2016510763A (ja) 2016-04-11
ZA201505966B (en) 2017-03-29
US20170252407A1 (en) 2017-09-07
SG11201506490TA (en) 2015-09-29
AU2016203028C1 (en) 2017-06-01
TN2015000385A1 (en) 2017-01-03
TW201444865A (zh) 2014-12-01
CY1120729T1 (el) 2019-12-11
MX2015011963A (es) 2015-12-09
EP2964250A1 (en) 2016-01-13
AU2014225348A1 (en) 2015-09-10
BR122016021558B1 (pt) 2023-03-28
CN111808182A (zh) 2020-10-23
AP2015008675A0 (en) 2015-08-31
BR122016021558A2 (pt) 2019-07-30
HRP20181269T1 (hr) 2018-10-19
MX365157B (es) 2019-05-24
AU2016203028A1 (en) 2016-05-26
AU2016277608A1 (en) 2017-01-12
US9649359B2 (en) 2017-05-16
PH12015501983A1 (en) 2016-01-11
CN105025917B (zh) 2020-08-18
CO7461145A2 (es) 2015-11-30
AU2016203028B2 (en) 2017-02-02
PE20151528A1 (es) 2015-11-14
SI2964250T1 (sl) 2018-11-30
DK2964250T3 (da) 2018-08-06
KR102267341B1 (ko) 2021-06-21
JP2021178841A (ja) 2021-11-18
EP2964250B1 (en) 2018-05-16
AU2016277608B2 (en) 2018-04-05
US20200268849A1 (en) 2020-08-27
CL2015002443A1 (es) 2016-05-20
JP6918871B2 (ja) 2021-08-11
US20160008433A1 (en) 2016-01-14
AU2014225348B2 (en) 2016-03-31
RS57446B1 (sr) 2018-09-28

Similar Documents

Publication Publication Date Title
ES2684349T3 (es) Péptidos y composiciones para el tratamiento de daños de las articulaciones.
US20220402987A1 (en) Peptides and compositions for treatment of joint damage
HK40038214A (en) Peptides and compositions for treatment of joint damage
HK1260928A1 (en) Peptides and compositions for treatment of joint damage
HK1214754B (en) Peptides and compositions for treatment of joint damage